ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T
2017
Background
Ataxia Telangiectasia (AT) is a rare incurable genetic disease, caused by biallelic mutations in the Ataxia Telangiectasia-Mutated (ATM) gene. Treatment with glucocorticoid analogues has been shown to improve the neurological symptoms that characterize this syndrome. Nevertheless, the molecular mechanism underlying the glucocorticoid action in AT patients is not yet understood. Recently, we have demonstrated that Dexamethasone treatment may partly restore ATM activity in AT lymphoblastoid cells by a new ATM transcript, namely ATMdexa1.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
32
References
8
Citations
NaN
KQI